Similar articles

• Meta-analysis of the role of platinum compounds in advanced ovarian carcinoma. The Advanced Ovarian Cancer Trialists Group.

  Williams CJ, Stewart L, Parmar M, Guthrie D. Williams CJ, et al. Semin Oncol. 1992 Feb;19(1 Suppl 2):120-8. Semin Oncol. 1992. PMID: 1411623
• Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group.

  [No authors listed] [No authors listed] BMJ. 1991 Oct 12;303(6807):884-93. doi: 10.1136/bmj.303.6807.884. BMJ. 1991. PMID: 1834291 Free PMC article.
• Biomarkers of platinum resistance in ovarian cancer: what can we use to improve treatment.

  van Zyl B, Tang D, Bowden NA. van Zyl B, et al. Endocr Relat Cancer. 2018 May;25(5):R303-R318. doi: 10.1530/ERC-17-0336. Epub 2018 Feb 27. Endocr Relat Cancer. 2018. PMID: 29487129 Review.
• Platinum or nonplatinum in recurrent ovarian cancer: that is the question.

  Poveda A, Marth C. Poveda A, et al. Future Oncol. 2017 Oct;13(23s):11-16. doi: 10.2217/fon-2017-0317. Epub 2017 Oct 11. Future Oncol. 2017. PMID: 29020823 Review.
• Quality of life and treatment response among women with platinum-resistant versus platinum-sensitive ovarian cancer treated for progression: a prospective analysis.

  Beesley VL, Green AC, Wyld DK, O'Rourke P, Wockner LF, deFazio A, Butow PN, Price MA, Horwood KR, Clavarino AM, Australian Ovarian Cancer Study Group, Australian Ovarian Cancer Study-Quality Of Life Study Investigators, Webb PM. Beesley VL, et al. Gynecol Oncol. 2014 Jan;132(1):130-6. doi: 10.1016/j.ygyno.2013.10.004. Epub 2013 Oct 11. Gynecol Oncol. 2014. PMID: 24125750